TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00905918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: All patients undergo biomarker analyses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: All patients undergo biomarker analyses
Study: NCT03282318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6294
Description: Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
Study: NCT02008474

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online weight loss + Incentives for weight loss 12 months
Description: Participants will be receive monetary incentives for reaching their weight loss goal at months 3 and 12.
Study: NCT04804423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)
Description: 38% silver fluoride will be applied to the surface of the isolated hypersensitive carious lesion followed by application of potassium iodide solution and according to manufacturer's instructions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride varnish (generic name; Duraphat®)
Description: 22,600 ppm sodium fluoride varnish will be applied on the surface of the affected hypersensitive active carious lesions.
Study: NCT00568230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant
Description: Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
Study: NCT03779217

Intervention type: OTHER
Intervention: screening mammography
Description: As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.
Study: NCT03282318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
Study: NCT03779217

Intervention type: OTHER
Intervention: screening mammography
Description: As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.

Intervention type: OTHER
Intervention: screening mammography
Description: As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.

Intervention type: OTHER
Intervention: screening mammography
Description: As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.

Intervention type: PROCEDURE
Intervention: mastoplasty and breast fat excission
Description: As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.

Intervention type: PROCEDURE
Intervention: mastoplasty and breast fat excission
Description: As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.

Intervention type: PROCEDURE
Intervention: mastoplasty and breast fat excission
Description: As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.

Intervention type: PROCEDURE
Intervention: mastoplasty and breast fat excission
Description: As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.
Study: NCT02936193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pylorus preservation
Description: Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal gastrectomy
Description: Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
Study: NCT03192202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM13
Description: AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM13
Description: AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
Study: NCT02155621

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genome sequencing
Description: Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis
Study: NCT02218047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-Proline-interferon alpha-2b
Description: Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available therapy (BAT)
Description: Best available therapy as selected by the investigator
Study: NCT02530125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pidilizumab
Description: Given IV
Study: NCT02162251

Intervention type: DRUG
Intervention: Donepezil Hydrochloride
Description: Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
Study: NCT04402762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovine Enoxaparin
Description: The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovine Enoxaparin
Description: The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Prefilled Syringe [Lovenox]
Description: The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Prefilled Syringe [Lovenox]
Description: The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.
Study: NCT03635515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gentlewave
Description: The Gentlewave system from Sonendo is a FDA cleared root canal irrigation device that uses broad spectrum acoustic energy, internally degassed distilled water, 3% NaOCl, and 8% EDTA to allow for a more thorough cleaning within the tooth. The fluids work to remove necrotic tissue, debris, biofilm, and bacteria while leaving dentin intact and preserving tooth structure. The Gentlewave irrigation replaces the NaOCl ultrasonic activation and EDTA steps of the standard endodontic protocol. Use of the Gentlewave system is contraindicated in teeth with immature apices, teeth with insufficient coronal structure, and teeth with root apices extending into the maxillary sinus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endodontic Protocol
Description: The tooth will be sufficiently anesthetized with local anesthetic. The tooth will be rubber dam isolated. The pulp chamber will be accessed removing all caries, defective restorations, and defective crowns. EAL and radiographs will be used to determine the working length of each canal, all canals will be cleaned and shaped using rotary files to at least a size 25.04 canal size to within 0.5 to 1 mm of the apical terminus. Between each file 5.25% NaOCl will be used to disinfect and clear the canals of debris. A final passive ultrasonic activation of NaOCl will be done for 30 seconds per canal. Each canal will then soak in 17% EDTA for 1 minute, rinsed in 5.25% NaOCl, and finally undergo a final rinse of 95% ethanol. Canals will be obturated with root canal sealer and gutta-percha.
Study: NCT01742988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Study: NCT03782012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported
Description: Visual organization of knowledge base items plus discourse-based discussion supporting knowledge availability and accessibility

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported
Description: Visual organization of knowledge base items plus discourse-based discussion supporting knowledge availability and accessibility
Study: NCT04023227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Description: 50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 5 mg and 10 mg will be available for dose adjustments.
Study: NCT06315595

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT04197869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Powder
Description: Polyethylene Glycol 3350 17g should be mixed in 8 ounces of fluid for administration. Polyethylene glycol is a high molecular weight, water soluble polymer which can form hydrogen bonds with water molecules. It is an osmotic laxative solution which stimulates bowel movements by increasing the amount of water absorbed in the GI tract. It decreases feces consistency and increases their volume by promoting peristalsis and evacuation. The side effects of polyethylene glycol are bloating, gas or diarrhea. The half-life of polyethylene glycol is 4-6 hours and after 18 hours the concentration declines to non-quantifiable levels.
Study: NCT03436394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Subjects will be administered a single oral dose of evobrutinib under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Subjects will be administered a single oral dose of evobrutinib under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Subjects will be administered a single oral dose of evobrutinib under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Subjects will be administered a single oral dose of evobrutinib under fasting conditions.
Study: NCT01763944

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
Study: NCT04408573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling deep brain stimulation
Description: Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling deep brain stimulation
Description: Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling deep brain stimulation
Description: Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF
Study: NCT00617344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent CYD Dengue Vaccine , 5555 formulation
Description: A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent CYD Dengue Vaccine , 5553 formulation
Description: A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent CYD Dengue Vaccine, 4444 formulation
Description: A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
Study: NCT03364127

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Acupuncture
Description: Active Acupuncture two times per week for 5 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture
Description: Placebo Acupuncture two times per week for 5 weeks
Study: NCT02696148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: For subcutaneous (s.c., under the skin) injection once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study: NCT05071157

Intervention type: BEHAVIORAL
Intervention: echocardiography
Description: * speckle tracking echocardiography~* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)~* bioimpedance~* blood test for biological assays (metabolomic analysis)

Intervention type: BEHAVIORAL
Intervention: echocardiography
Description: * speckle tracking echocardiography~* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)~* bioimpedance~* blood test for biological assays (metabolomic analysis)
Study: NCT01846637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sleeve gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Study: NCT02333071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Description: A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bremelanotide
Description: A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01963442

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-ray
Description: at Day 0, Day 30 and relapse

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Chest X-ray
Description: at Day 0, Day 30 and relapse

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: 2 tablets 3 times a day for 5 days from Day 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Augmentin)
Description: 2 tablets 3 times a day for 5 days from Day 3
Study: NCT05071157

Intervention type: BEHAVIORAL
Intervention: echocardiography
Description: * speckle tracking echocardiography~* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)~* bioimpedance~* blood test for biological assays (metabolomic analysis)
Study: NCT02756767

Intervention type: OTHER
Intervention: Survey
Study: NCT04885023

Intervention type: OTHER
Group type: OTHER
Intervention: Hippotherapy
Description: The hippotherapy program for 10 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The hippotherapy program for 10 weeks
Study: NCT00781976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7295
Description: 700mg per day maximum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT02115958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cancer stem cell vaccine
Study: NCT00983073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period.
Study: NCT01029223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivabradine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03784339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy + education
Description: Participants will take part in a 30 minute education session surrounding fear of movement and catastrophizing thoughts. They will then receive standard care, which will involve strength exercises and taping if needed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy
Description: Standard physiotherapy care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Standard physiotherapy care
Study: NCT01373528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide irrigation
Description: A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
Study: NCT02450318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow-paced walking
Description: Subjects will walk on a treadmill at a slow pace for 47 minutes
Study: NCT03166761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone injection into the sacroiliac joint

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone injection into the sacroiliac joint
Study: NCT03217110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
Study: NCT01525732

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Per Oral Endoscopic Myotomy
Study: NCT01767740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULTRABRAID PLUS SUTURE
Description: Rotator Cuff Repair with ULTRABRAID PLUS SUTURE

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ULTRABRAID SUTURE
Description: Rotator Cuff Repair with ULTRABRAID SUTURE
Study: NCT03133975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Treatment)
Description: Single high dose vitamin D3 in treatment of dyslipedemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed diet of carbohydrate and protein (Control)
Description: Mixed diet of carbohydrate and protein
Study: NCT04440566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study: NCT03459430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training
Description: Effect of different core stability programs using diverse training intensities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training
Description: Effect of different core stability programs using diverse training intensities
Study: NCT02243943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study: NCT00624299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox injection (100 ius) per muscle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline injection
Study: NCT02495272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 10IU Administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin 10IU Administered intramuscularly.